Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: December 2006
-
By Jason Derry — Genentech and AC Immune have announced a $300 million licensing agreement relating to the development of antibodies for treating Alzheimer's disease. AC Immune's research in the Alzheimer's area includes inducing anti-beta amyloid antibody production in patients. The announcement marks the third recent major licensing deal between Genentech and a…
-
By Jason Derry — Targeted Genetics Corp. has announced a non-exclusive licensing deal with Amsterdam Molecular Therapeutics B.V. relating to the use of the AAV1 (Adeno-Associated Virus Type 1) vector. The licensed AAV1 vector is covered by U.S. Patent Nos. 6,759,237 and 7,105,345. AMT intends to use the vector for developing therapeutics for…
-
By Christopher P. Singer — The U.S. Patent and Trademark Office will be releasing an updated version of private PAIR (Patent Application Information Retrieval), which allows registered practitioners access to information regarding their patent applications electronically. To announce the launch, the USPTO will be holding a webinar on Tuesday, December 19, 2006 at…
-
By Donald Zuhn — In an appeal from a District Court decision granting a preliminary injunction in favor of Plaintiffs-Appellees Sanofi-Synthelabo, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (Sanofi), the Federal Circuit concluded that the District Court did not abuse its discretion in granting preliminary injunctive relief, and thus, affirmed the District…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma patent cases. A few interesting cases will be selected for periodic monitoring, providing our readers with an opportunity to follow the progress of these cases. Stephen J. Smith Trust et. al. v. Ethicon, Inc.1:06-cv-02371;…
-
By Jason Derry — The Milken Institute, an independent think tank, has released a report that proposes a strategy that may stimulate increased funding efforts for early-stage biotech research. The strategy essentially involves public-private partnerships. The need to stimulate funding efforts for biomedical research stems from decreased or stagnant public funding, and from…
-
By Donald Zuhn — In response to the adoption of Federal Rule of Appellate Procedure 32.1, the Federal Circuit has adopted new Federal Circuit Rule 32.1. Under the new Rule, parties will no longer be prohibited or restricted from citing nonprecedential dispositions issued by the Federal Circuit after January 1, 2007. The new Rule…
-
By Kevin Noonan — Once again, the popular press, aided and abetted by academics more interested in career advancement than the facts, have sounded the clarion call against patenting genes (see "Gene Patenting in the News Again"). For anyone interested in a reasoned debate on an important topic, the resulting articles are disheartening. …
-
By Christopher P. Singer — I am always impressed by the variety of investment vehicles and innovative methods that investors and businesses use to generate money. Back on October 25, 2006, Ocean Tomo, an intellectual capital merchant banc that specializes in a variety of services related to intellectual property, announced the launch of…
-
By Jason Derry — The public health ministry in Thailand has officially announced that it will permit Thailand's public drug maker, the Government Pharmaceutical Organization, to manufacture a generic version of Merck's AIDS drug, Efavirenz, for a 5 year period. The compulsory license was made by the acting Thai military government, who declared…
Patent Docs 